|
|
|
28.10.25 - 13:12
|
Fosun Pharma Announces 2025Q3 Financial Results (PR Newswire)
|
|
|
Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group";......
|
|
|
28.10.25 - 10:45
|
Results: FOSUN PHARMA 1-3Q NP RMB2.523B Up 25.5% YoY (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that its operating revenue for the third quarter this year was RMB9.879 billion, down 5.46% YoY. The net profit attributable to shareholders was RMB821 million, up 4.52% YoY, with an EPS of RMB0.31.~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
20.10.25 - 01:36
|
Unmet healthcare demand in Asia presents Chinese hospitals with opportunities (SCMP)
|
|
|
Driven by accelerating healthcare demand, Fosun Health plans to target markets in South Asia, Southeast Asia and the Middle East to capitalise on their economic growth and fragmented health systems, according to chairman and CEO Frank Hu Hang.
The subsidiary of Hong Kong-listed Shanghai Fosun Pharmaceutical (Group) operates 19 hospitals, clinics and third-party diagnostics centres in mainland China. Four of these are in Foshan, Guangzhou, Shenzhen and Zhuhai – cities that are part of the Greater......
|
|
|
|
|
16.09.25 - 10:36
|
Fosun′s Henlius in talks with Johnson & Johnson, Roche on cancer drug (SCMP)
|
|
|
Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar with the matter said.
An agreement could fetch the subsidiary of Shanghai Fosun Pharmaceutical at least several hundred million dollars up front and then more in milestone payments down the road based on the drug's performance, the people said. They asked not to be identified because the......
|
|
|
08.09.25 - 06:15
|
Midday Takeaway: HSI Closes Midday at 25,508, Up 90 pts; HSTI Closes Midday at 5,702, Up 15 pts; BABA Up over 3%; WUXI BIO, CHOW TAI FOOK, FOSUN PHARMA, HORIZONROBOT-W, CHINA LESSO Hit New Highs (AAStocks)
|
|
|
At midday close, HSI rose 90 pts or 0.4% to 25,508. HSTI rose 15 pts or 0.3% to 5,702. HSCEI gained 15 pts or 0.2% to 9,072.Active Heavyweights:BABA (09988.HK) closed at $136.7, up 3.7%XIAOMI (01810.HK) closed at $54.3, up 1.2%TENCENT (00700.HK) closed at $612, up 1.1%MEITUAN (03690.HK) closed at $102.5, down 0.5%HSI & HSCEI Con......
|
|
|
|
|
26.08.25 - 14:45
|
Fosun Pharma Announces 2025 Interim Results (PR Newswire)
|
|
|
Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company,......
|
|
|
|
|
12.08.25 - 04:00
|
H Shrs: HSI Loses 82Pts at Open; BABA-W Soft; FOSUN PHARMA Rebounds (AAStocks)
|
|
|
Following a joint U.S.-China statement announcing a further 90-day suspension of reciprocal 24% tariffs, Hong Kong bourse opened lower as markets awaited U.S. inflation data. The HSI dipped 82 points or 0.3% to 24,824, the HSCEI dropped 30 points or 0.3% to 8,858, and the HSTECH declined 32 points or 0.6% to 5,427.For techs, BAB......
|
|
|
|
|
|
|
|
|
26.06.25 - 12:33
|
Nature′s Sunshine Products, Inc. Announces Pricing of Secondary Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions....
|
|
|
25.06.25 - 22:03
|
Nature′s Sunshine Products, Inc. Announces Launch of Secondary Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”)....
|
|
|
16.06.25 - 15:30
|
Teva, Shanghai Fosun Partner To Develop TEV-56278 (AFX)
|
|
|
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278 ut......
|
|
|
|
|
06.06.25 - 11:15
|
FOSUN PHARMA Repurchases 800K A-Shrs, Involving ~RMB20M (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK)(600196.SH) announced that it repurchased a total of 800,300 shares of the company on the Shanghai Stock Exchange today (6th), with the price per share ranging from RMB24.92 to RMB25.14, involving a total of approximately RMB19.9988 million. ~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
|
|
12.05.25 - 07:15
|
Research: Citi Lists H-shrs w/ US Exports (Table) (AAStocks)
|
|
|
Stock│Forecast for Percentage of Revenue from Export to US in 2025COWELL (01415.HK)│30%ASMPT(00522.HK)│15%BYD ELECTRONIC (00285.HK)│around 25-30%.KLN (00636.HK)│15-20%AAC TECH (02018.HK)│12%FOSUN PHARMA (02196.HK)│11%SUNNY OPTICAL (02382.HK)│9%Q TECH (01478.HK)│<1%CHERVON ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
